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Key point
Statins have shown poten-
tial beneficial effects in
chronic inflammatory dis-
eases, including chronic
lung diseases, neurological
disorders and chronic kid-
ney disease.
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Elisa Pose1,2, Jonel Trebicka4,5,6,7, Rajeshwar P Mookerjee8, Paolo Angeli9, Pere Ginès1,2,3,⇑SummaryKeywords: Statins; PleiotropicIn addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-
inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory
conditions. Statins have only recently been investigated as a potential treatment option in chronic liver
diseases because of concerns related to their safety in patients with impaired liver function. A number of
experimental studies in animal models of liver diseases have shown that statins decrease hepatic
inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large popu-
lations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins,
with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease pro-
gression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial
effects persisted after adjustment for disease severity and other potential confounders. Finally, a few
randomised controlled trials have shown that treatment with simvastatin decreases portal pressure
(two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients
developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects,
further randomised controlled trials in large series of patients with hard clinical endpoints should be
performed before statins can be recommended for use in clinical practice.
 2018 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Statins were discovered as a by-product in the
research for new antimicrobial agents.1 They rep-
resent a heterogeneous group of molecules that
inhibit the activity of hydroxymethylglutaryl-
coenzyme A (HMG CoA) reductase, a key enzyme
in the synthesis of cholesterol. Thus, statins are
used for the management of dyslipidaemia, world-
wide.2 Besides their lipid-lowering property, sta-
tins also exhibit multiple pleiotropic effects such
as antioxidative, antiproliferative and anti-
inflammatory properties, as well as the capacity
to improve endothelial function and to stimulate
neoangiogenesis.3 It is not known to what extent
these effects are related to the primary effect of
these drugs, nevertheless, several studies have
demonstrated that statins significantly reduce
the risk of cardiovascular morbidity and mortal-
ity.4 As a consequence, statins are among the most
prescribed class of medications worldwide and an
increasing number of patients have received sta-
tins as primary or secondary prophylaxis for car-
diovascular events in the last decades in all
developed countries.5 It is well known that statins
can cause elevations in serum aspartate and ala-
nine aminotransferase levels. Thus, there is still
some residual concern among primary care physi-
cians in prescribing statins to patients with under-
lying liver disease, since some of them still think
that these patients may be at increased risk of
hepatotoxicity.6 However, liver damage due to sta-
tins is extremely rare and the exact mechanism byJournal of Hepatology 2019 vol. 70 j 1which they cause aspartate and alanine amino-
transferase elevation is still uncertain. An eleva-
tion of liver enzymes >3 times the upper limit of
normal has been observed in <1% of treated
patients.7,8 Paradoxically, several studies have
recently shown that statins might offer clinical
benefits in the setting of liver disease, including
in non-alcoholic fatty liver disease (NAFLD), chole-
static liver diseases, and cirrhosis. In particular,
this class of drugs was shown to ameliorate func-
tional alterations and liver histology in patients
with NAFLD, while also reducing their risk of
cardiovascular events.9 In addition, the use of
statins in patients with cirrhosis has been shown
to reduce portal hypertension, as estimated by a
significant decrease in hepatic venous pressure
gradient (HVPG), and reducing the risk of decom-
pensation and death.10 Thus, despite statins
being considered ‘forbidden-drugs’ in patients
with increased liver enzymes for several years,
nowadays there is a growing interest in their
potential benefits in patients with liver diseases.Rationale for the use of statins in chronic
disorders
As mentioned, beyond their role in lipid lowering
and consequent application in patients with
known cardiovascular risks, statins have pleiotro-
pic effects that target key processes in the patho-
physiology of many chronic diseases. Firstly, they94–202
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OF HEPATOLOGYact on inflammation by: i) decreasing leukocyte
adhesion to endothelia and epithelial cells by
inhibiting expression and binding of LFA-1 and
ICAM-1; ii) decreasing the production of NF-kB
and hence the release of pro-inflammatory cytoki-
nes such as TNFa and IL-6; and iii) blocking of
prenylation of key proteins required for the forma-
tion of lipid rafts and immune cell activation and
growth.11,12 Statins also decrease the level of
oxidative stress by reducing the levels and oxida-
tion of low density lipoprotein, in addition to
reducing inducible nitric oxide (iNOS) production,
and thereby impacting on nitrosative stress.13,14
Moreover, statins promote the mobilization and
activation of endothelial progenitor cells, impor-
tant for angiogenesis and regenerative capacity.15
The ability of statins to decrease inflammation
and promote healing has been shown to be bene-
ficial in many chronic diseases, ranging from
obstructive airways disease to neurodegenerative
disorders, examples of which are elaborated on.
Chronic lung diseases
The pathophysiology of chronic obstructive lung
disease involves i) enlargement of distal airways
and destruction of their walls in the absence of
fibrosis (emphysema) and ii) a remodelling and
narrowing of small airways predominantly in
smokers, whereby fibrosis, mucus hypersecretion
and metaplasia, increase airway wall thickness.16
In these scenarios, there is a chronic stimulation
of the innate immune system, with migration of
immune cells to the lungs, resulting in the gener-
ation of pro-oxidants and the release of inflamma-
tory cytokines.17 Indeed, patients with increased
inflammatory indices such as C-reactive protein
(CRP) are at increased risk of chronic obstructive
pulmonary disease (COPD) exacerbations and
more rapid decline in lung function.18
As previously described, many of these patho-
logical processes lend themselves to targeting by
statins. A large series of 14,000 patients with
COPD from Taiwan showed that those taking sta-
tins had decreased hospitalisations and a 30%
reduction in COPD exacerbations.19 Whilst a
reduction in mortality has not been universally
shown in prospective studies of patients with
COPD on statins vs. those not on treatment,20 sev-
eral cohort based retrospective studies have
shown a reduction in all-cause mortality ranging
from 21–35%.21,22 However, it is important to note
that further critique of controlled trial data sug-
gests that these retrospective studies failed to
exclude patients with cardiovascular indications
for starting statin therapy. Thus, any perceived
benefit was likely from improved clinical out-
comes in patients enrolled with cardiovascular
disease or risk (elevated baseline cholesterol or
CRP).23,24 These studies resulted in the suggestion,
in the GOLD guidelines for management of COPD,
that statin therapy should not be recommended
to reduce exacerbations of COPD in patients withJournal ofno risk factors for cardiovascular disease [GOLD
2017 http://www.goldcopd.org].
Neurological disorders
The benefits of lipid lowering after ischaemic cere-
brovascular events are well established, but given
the anti-inflammatory effects and vascular remod-
elling actions of statins, other neurological condi-
tions have also been explored. One such state is
chronic subdural haematoma, where there is
impaired angiogenesis in the neomembrane of the
haematoma and also localised inflammation.25
Atorvastatin has been shown to improve angiogen-
esis and increase the levels of circulating endothe-
lial progenitor cells through activation of
endothelial nitric oxide synthase (eNOS) and the
threonine kinase Akt, in preclinical models of
chronic subdural haematoma.26 Moreover, statins
facilitate the migration of endothelial progenitor
cells by blocking inhibitory miR-221 and miR-222,
as has been studied in cultured human endothelial
cells.27 Furthermore, the anti-inflammatory effect
of statins has been shown to promote functional
recovery in rats with induced subdural
haematoma.28 In addition, a meta-analysis of ran-
domised controlled trials (RCTs) of statin therapy
suggested that statins promote a significant reduc-
tion in vascular endothelial growth factor (VEGF)
level.29 VEGF is believed to be in high concentra-
tions in haematoma fluid and increases its volume;
VEGF inhibition with statins might be beneficial in
managing the early impact of chronic subdural hae-
matomas. However, a detailed clinical evaluation of
statin therapy in patients with chronic subdural
haematomas is still awaited.
Inflammatory cascades, oxidant stress, micro-
glial activation and the aggregation of a-
synuclein, all contribute to the development of
progressive and debilitating neurodegenerative
disorders, such as Parkinson’s disease (PD). These
processes are all positively impacted upon by
statins.30 Simvastatin is known to effectively cross
the blood brain barrier and enter the substantia
nigra, decreasing the activation of NF-jB and
pro-inflammatory cascades, and restoring locomo-
tor function in a murine model of PD.31,32
Similarly, pitavastatin and atorvastatin have
been shown to protect against senile plaque for-
mation and reduce microglial activation in a
rodent model of Alzheimer’s disease.33 These find-
ings also extend to models of cerebral injury after
cardio-pulmonary bypass, where neuronal loss
and memory impairment are prevented by sim-
vastatin therapy.34 In addition to these preclinical
results that support the use of statins in neurolog-
ical disorders, retrospective reviews of patients on
lipid-lowering therapy have suggested that statin
therapy improves global cognition in patients with
PD,35 or delays the onset of PD.36 A meta-analysis
of over three million individuals with over 21,000
incident cases of PD, suggested a lower risk of PD
in those patients on statin therapy.37Hepatology 2019 vol. 70 j 194–202 195
Key point
Studies in animal models
of liver diseases have
shown that statins reduce
liver fibrosis, improve
endothelial dysfunction
and decrease portal
pressure.
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196Chronic kidney disease
Whilst application of statins to patients with kid-
ney dysfunction secondary to diabetes mellitus is
standard practice, and has been suggested to
reduce the risk of diabetes complications, statins
have also been shown to decrease the risk of vas-
cular events in patients with advanced chronic
kidney disease (CKD). The SHARP study showed
patients treated with simvastatin plus ezetimibe
had significantly fewer atherosclerotic events
(17%), especially non-haemorrhagic stroke, over a
median follow-up of just under five years, com-
pared to patients not receiving lipid-lowering ther-
apy.38 In addition, a further study in over 14,000
patients with predialysis advanced CKD, showed
reduced all-cause mortality and reduced risk of
needing future dialysis in patients treatedwith sta-
tins compared to those not treated.39 Of note, in
this study, there was no apparent reduction in risk
of ischaemic stroke or intracranial haemorrhage.
The aforementioned examples highlight the
potential benefits of statin therapy in chronic dis-
eases, arguing for the use of statins beyond their
traditional cardiovascular applications. Statins
may be particularly relevant in cases where there
is a need to lower systemic inflammation, enhance
vascular regeneration and reduce oxidative stress.Statins in liver diseases
Studies in experimental liver diseases
Effects of statins on steatosis
Traditionally, statins have been used in patients
with metabolic syndrome (MS) and dyslipidaemia,
since statins decrease LDL cholesterol levels in
serum. Animals and patients with MS usually dis-
play NAFLD and its progressive form of non-
alcoholic steatohepatitis (NASH).40 By decreasing
LDL and activating sterol regulatory element-
binding proteins (SREBPs), peroxisome
proliferator-activated receptor alpha (PPARa) and
b-oxidation, statins may reduce hepatic steato-
sis.41 This hepatoprotective effect of statins has
already been demonstrated in steatotic livers of
animal models of transplantation,42 but not in a
combined genetic and dietary model of NASH.40,43
Therefore, the beneficial effects of statins in exper-
imental steatosis remain controversial.
Effects of statins on inflammation and fibrosis
Statins have shown anti-inflammatory and antifi-
brotic effects in experimental models of chronic
liver injury. Statins exert anti-inflammatory
effects via the inhibition of small GTPase prenyla-
tion and the decrease in downstream signalling.43
The potential beneficial effects of statins in
fibrosis have been assessed in different experi-
mental models of chronic liver injury. In experi-
mental NASH, statins affect the paracrine
signalling of hepatocytes on hepatic stellate cells
(HSCs),44 blocking hepatic stellate cell (HSC) acti-
vation and fibrogenesis.43,44Journal of Hepatology 2019 vol. 70 j 1In a bile duct ligated (BDL) mouse model, the
antifibrotic effect of statins seems to be mediated
via a reduction in serum bile acid levels, which is
at least partly due to activation of pregnane X
receptor and PPARa.45 The antifibrotic effect
appears to be marked in early stages of BDL-
induced liver injury, while in later stages the
aggressiveness of the BDL model overrides the
beneficial effects of statins.46 In this model, fibro-
genesis is also attenuated as shown by the levels
of collagen fragments as a readout of remodelling
during fibrogenesis47 and by a reduction in HSC
activity,46 most likely due to induction of senes-
cence.48 Statins may also improve fibrosis by
inhibiting the RhoA/Rho-kinase pathway in HSCs
and by restoring the sinusoidal endothelial func-
tion through KLF2 induction.49
In other animal models, such as angiotensin-II
induced liver fibrosis, statins have also been
shown to decrease fibrosis by reducing inflamma-
tory activity.50 Overall, statins improve fibrosis
progression in different models of chronic liver
injury.
Effects of statins on portal hypertension
All aetiologies of liver disease share a common
end-stage, which is characterised by profound
liver remodelling and portal hypertension. An
additional dynamic component of increased intra-
hepatic resistance is an imbalance in the vascular
tone-regulating pathways (RhoA/Rho-kinase and
nitric oxide [NO]) showing a shift towards vaso-
constriction. All these pathways may be modu-
lated by statins.49,51–53 While statins inhibit
translocation of RhoA and, thus, the activity of
Rho-kinase,52 they improve endothelial dysfunc-
tion by increasing the activity of eNOS and the
availability of NO.52,54 As mentioned before, by
modulating Rho-kinase activity and also KLF2
expression statins also show anti-fibrotic proper-
ties that may contribute to reducing portal hyper-
tension.53 Statins can thereby modulate the
dynamic as well as the structural (fibrosis) compo-
nents of chronic liver diseases and be potentially
useful in the management of cirrhosis with portal
hypertension. The possible intracellular mecha-
nisms of statins in liver cells are shown (Fig. 1).
Effects of statins on oncogenesis
Statins might also exert antineoplastic properties.
Besides inhibition of cell proliferation in vitro, sta-
tins might also induce apoptosis of hepatoma cells
and inhibit intrahepatic angiogenesis.55 Interest-
ingly, the anti-angiogenic effect is dependent on
the context of chronic liver disease; while in
experimental cirrhosis statins have beneficial
effects, in experimental non-cirrhotic portal
hypertension statins increase intrahepatic angio-
genesis and aggravate portal hypertension.56
Reduced proliferation might be due to interference
with KRAS and prevention of p21 and 27 break-
down in malignant cells followed by induction of94–202
Key point
In patients with cirrhosis,
statins have shown poten-
tial beneficial effects by
decreasing portal hyper-
tension and risk of decom-
pensation and may
improve survival.
Key point
In patients with pre-
cirrhotic conditions, statins
may have beneficial effects
by preventing disease
progression.
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integrins and Rho-kinase, which are expressed at
the cell membrane, have been shown to reduce
proliferation as well as tumour cell adhesion in
an in vitro model of hepatocellular carcinoma.59
Studies in human liver diseases
There is limited information available on the
effects of statins in patients with liver diseases.
Earlier studies were aimed at assessing the safety
of statins because of the potential concern that
liver disease could increase the frequency and/or
severity of hepatic injury related to statins and
did not focus on the possible beneficial effects of
these drugs.59–61 Nevertheless, in recent years a
number of studies have assessed the potentially
beneficial anti-inflammatory and antifibrotic
actions of statins in the course of chronic liver
injury in patients. These studies, together with
preclinical evidence, deliver the rationale for the
use of statins in chronic liver diseases.62 In the fol-
lowing two sub-sections we focus on these stud-
ies, separating our analysis into pre-cirrhotic
conditions and cirrhosis.
Effects in patients with pre-cirrhotic conditions
The effects of statins have mainly been assessed in
patients with chronic hepatitis B virus (HBV) or
hepatitis C virus (HCV) infections without cirrho-
sis. All investigations were performed in
retrospective-cohorts, including several thousand
patients, in which the evolution of patients treated
with statins for hypercholesterolemia was com-
pared with that of patients not treated with sta-
tins.63–65 Unfortunately, no RCTs have been
performed. Cohorts were derived mainly from
detailed patient databases that contained informa-
tion about patient outcomes and prescribed drugs,
specifically, the Veterans Affairs Administration
and the Taiwan’s National Health Insurance.63–65
The outcomes analysed were disease progression,
as estimated by the development of cirrhosis or
increase in serological markers of fibrosis during
follow-up, improved response to interferon-
based antiviral therapy, development of hepato-
cellular carcinoma, and mortality. The strengths
of these studies are the large number of patients
evaluated and the adjustment for confounding fac-
tors. Interestingly, the results of these studies
show that statins have a favourable effect on the
natural history of HBV and HCV infection by
decreasing disease progression to cirrhosis and
reducing mortality.63–65 In one study, statin use
also reduced the development of hepatocellular
carcinoma.65 A meta-analysis performed with all
studies reported until 2016 concluded that statins
may delay the progression of fibrosis and reduce
hepatic decompensation and mortality.66 How-
ever, these studies are affected by a number of
limitations that reduce the validity of the findings,
including their retrospective nature, uncertainty
about some characteristics of statin use (dose,Journal ofduration), and difficulty in assessing some of the
endpoints. Therefore, statins cannot be recom-
mended as therapy for pre-cirrhotic conditions
until high-quality data derived from RCTs are
available.
Surprisingly, there is very limited information
on the effects of statins in patients with NAFLD
despite the fact that many of these patients have
indications for treatment with statins. For many
years, there was concern that statins might have
deleterious effects in patients with NAFLD, by
causing liver injury or increasing liver lipogenesis,
at the same time as increasing hepatic LDL recep-
tor expression.67 Contrary to expectations, two
recent studies showed that statins are not only
safe in patients with NAFLD but they could also
be beneficial by decreasing steatosis and fibrosis,
and preventing disease progression.68,69 However,
since this information derives from retrospective
cohort studies, prospective studies are needed to
confirm these beneficial effects.
Effects in patients with cirrhosis
The effects of statins have also been assessed in
patients with cirrhosis. To the best of our knowl-
edge, nine studies have been reported, all of them
in recent years: five retrospective cohort stud-
ies70–74 and four RCTs.75–78 The characteristics
and results of these studies are summarised
(Table 1). The main aetiologies of cirrhosis in the
different studies were HCV or HBV infection and
alcohol consumption. Only one study included
patients with cirrhosis related to NAFLD.73 Cohort
studies included large numbers of patients (up to
19,379 in the largest study)74 and were derived
from detailed patient databases in which the main
endpoints were decompensation of cirrhosis and
death in four studies,70–73 and development of
infections in one.74 Patients treated with statins
during follow-up were compared with those not
treated with statins and endpoints were adjusted
for themost important confounding variables. Sim-
vastatin was the most frequent statin used in all
studies. The majority of studies used unmatched
analysis together with propensity score matched
analysis. Statins consistently reduced the risk of
decompensation and death in all studies (hazard
ratios ranging from 0.29 to 0.58 and 0.46 to 0.66
for decompensation and death, respectively). In
addition, one of the studies showed a reduction in
the risk of developing hepatocellular carcinoma.70
Three randomised, placebo-controlled, double-
blind trials have been reported assessing the effect
of simvastatin (40 mg/day for one or three
months) or atorvastatin (20 mg/day for one
month) on portal pressure, as estimated by HVPG,
in a small series of patients with cirrhosis and por-
tal hypertension.75–77 Most patients were Child-
Pugh A and had compensated cirrhosis and very
few had Child-Pugh C cirrhosis. Statin therapy
was associated with a decrease in portal pressure,
as estimated by HVPG, whereas no significantHepatology 2019 vol. 70 j 194–202 197
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Fig. 1. Pleiotropic effects of statins on small GTPases in the liver. The decrease in activation of small GPTases RhoA and Ras in hepatic stellate cells and liver
sinusoidal endothelial cells leads to changes in the subsequent signalling pathways, which results in less fibrogenesis, less hepatic inflammation and lower
portal pressure. Additional statins have direct effects on hepatocyte growth and proliferation signals and thereby might abrogate the development of
hepatocellular carcinoma.
Key point
RCTs in large series of
patients are needed to con-
firm safety and beneficial
effects of statins in patients
with cirrhosis.
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198changes were observed in patients treated with
placebo. Moreover, in 32% and 60% of patients
treated with simvastatin and in 91% of patients
treated with atorvastatin in the three studies, the
decrease in HVPG was greater than 20%, indicating
a clinically significant reduction in portal pressure
in a sizeable proportion of patients treated.
The results of the largest RCT on the effects of
simvastatin in cirrhosis were reported very
recently.78 In this study, 158 patients with cirrho-
sis and portal hypertension were randomised to
receive either simvastatin (20 mg/day for the first
two weeks followed by 40 mg/day) or placebo
during a two-year period. The main endpoint
was a composite of rebleeding and death. During
a median follow-up of approximately one year,
30 out of 78 (39%) patients in the placebo group
and 22 of the 69 (31.9%) patients in the simvas-
tatin group reached the primary endpoint (hazard
ratio 0.82; CI 0.47–1.43; p = 0.42). Nonetheless,
when only death was evaluated, mortality was
22% in the placebo group compared to 9% in the
simvastatin group (hazard ratio 0.39; CI 0.15–
0.99; p = 0.03). The decrease in mortality was
mainly due to a reduction in liver-related deaths.
Taken together, the results of cohort studies
and RCTs suggest that statins have a beneficial
effect on the evolution of cirrhosis by decreasing
the risk of decompensation and improving sur-
vival. These beneficial effects may be related to
the decrease in portal hypertension caused by
simvastatin, yet other possibilities cannot beJournal of Hepatology 2019 vol. 70 j 1excluded, particularly the possible effects of
statins in decreasing systemic and hepatic inflam-
mation. Nevertheless, further RCTs in large series
of patients with hard primary endpoints are
needed to confirm the beneficial effects of statins
on the outcome of patients with cirrhosis. In this
regard, a multicentre RCT assessing the effects of
the combination of simvastatin and rifaximin for
prevention of disease progression and acute-on-
chronic liver failure development in patients with
decompensated cirrhosis is being conducted in
several European countries [https://www.liver-
hope-h2020.eu/index_es.html].
Safety of statins in patients with liver diseases
Statins are one of the most prescribed drugs in
patients with hyperlipidaemia and for prevention
of cardiovascular events, and they are in general
well tolerated. In fact, drug-induced liver injury
related to statins is extremely rare (<2 cases/
1,000.,000 patient-years) and likely idiosyncratic
in nature.79,80 Nevertheless, one side effect of sta-
tins that may be of particular concern is muscular
toxicity. The spectrum of statin-associated muscle
toxicity is considered to include several distinct
entities, from myalgia to the most severe and less
frequent form, rhabdomyolysis.81 The risk of mus-
cle adverse events caused by statins seems to be
related to statins systemic exposure, so the risk
of statin-related muscle toxicity is increased in
patients treated with higher doses of statins,82
and also in patients with polymorphisms in a94–202
Table 1. Retrospective cohort studies and randomised clinical trials of statins in patients with cirrhosis.
Retrospective cohort studies
Study Patient
source
Patient
description
Study design Number of
patients
Type of statin Follow-up
period
Endpoints Results Comments
F. Chang
Hepatology 2017
Taiwan
National
Health
Insurance
HBV, HCV and
alcohol-related
cirrhosis
Retrospective
cohort study
1,174 statin
users vs. 6,453
non-statin users
NA Approx.
median of
follow-up of
3 years
Decompensation,
death, HCC
development
Prevented decompensation aHR
0.39 (0.30–0.50), decreased
mortality aHR 0.46 (0.34–0.63),
decreased HCC aHR 0.52 (0.35–
0.76)
Lower risk of ascites, variceal bleeding
and hepatic encephalopathy. Analysis by
aetiology in HBV, HCV and alcohol-
related cirrhosis. Dose-response
relationship
Bang
Aliment
Pharmacol Ther
2017
Danish
National
Patient
Registry
Alcohol-related
cirrhosis
Retrospective
cohort study
794 statin users
vs. 4,623 non-
users
Simvastatin 79%
Atorvastatin 8%
Rosuvastatin 6%
Approx.
median of
follow-up of
4 years
Decompensation,
death
Prevented decompensation HR
0.29 (0.24–0.34), decreased
mortality HR 0.57 (0.45–0.71)
Adjusted by adhesion to treatment but
not for liver function scores. HE not
evaluated
Mohanty
Gastroenterology
2016
US
Veterans
Health
Admin
HCV-related
compensated
cirrhosis
Retrospective
cohort study
1,323 statin
users vs. 12,522
non-statin users
Simvastatin 85%
Lovastatin 10%
Pravastatin 3%
Rosuvastatin 1%
Fluvastatin 1%
Median of
2.5 years for
statin users,
1.5 years for
non-users
Decompensation,
death
Prevented decompensation aHR
0.55 (0.39–0.77), decreased
mortality aHR 0.56 (0.46–0.69)
Adjusted for liver tests and scores. Lower
risk of ascites and variceal haemorrhage
Kumar
Dig Dis Sci 2014
Partners
Research
Patient
Data
Registry
NASH, alcohol,
HBV and HCV-
related cirrhosis
Retrospective
cohort study
81 statin users
vs. 162 non-
statin users
Simvastatin 49%
Atorvastatin 30%
3 years for
statin users,
2.5 years for
non-statin
users
Decompensation,
death
Prevented decompensation HR
0.58 (0.34–0.98), decreased
mortality HR 0.66 (0.33–0.86)
Low number of patients included, risk of
selection and reporting bias. Biopsy
proven cirrhosis
C. M-Feagans
Aliment
Pharmacol Ther
2013
US
Veterans
Health
Admin
HCV and alcohol-
related cirrhosis
Retrospective
cohort study
2,468 statin
users vs. 16,408
non-statin users
Simvastatin 90%
Lovastatin 9%
3.3 years Infections Prevented infections aHR 0.67
(0.47–0.95)
Adjusted for age and comorbidities. No
data of liver function
Randomised clinical trials
Study Patient
source
Patient
description
Study design Number of
patients
Type of statin Follow-up
period
Endpoints Results Comments
Abraldes,
Gastroenterology,
2009
University
Hospitals
Cirrhosis and
portal
hypertension
(HVPG >12 mmHg)
Multicentre
randomised
clinical trial
(3 centres)
27 patients on
statin treatment
vs. 28 patients
on placebo
Simvastatin One month Change in HVPG Decreased HVPG from 18.5 to
17.1 (p = 0.003), not decrease in
placebo group
Simvastatin administration improved
quantitative tests of liver function
(indiocyanine green clearance). Non-
severe adverse events related to
medication
P. Pollo-Flores,
Digestive and
Liver Disease,
2015
University
Hospital
Cirrhosis and
portal
hypertension
(HVPG >5 mmHg)
Single centre
randomised
clinical trial
14 patients
under statins
treatment vs. 20
patients on
placebo
Simvastatin Three months Change in HVPG Reduced HVPG in patients under
statin treatment compared to
placebo: 2 vs. 0 mmHg, p = 0.02
Previous variceal bleeding independent
variable associated with response to
simvastatin. Non-severe adverse events
related to medication
Abraldes,
Gastroenterology,
2016
University
Hospitals
Cirrhosis and
variceal bleeding
5–10 days before
inclusion
Multicentre
randomised
clinical trial
(14 centres)
69 patients
under statin
treatment vs. 78
patients on
placebo
Simvastatin Two years Composite
endpoint
(rebleeding or
death), death
Non-significant decrease in risk
of rebleeding or death, decreased
mortality HR 0.39 (0.15–0.98)
Decrease in liver-related death Non-
significant decrease in the primary
endpoint or in specific complications of
cirrhosis
Bishnu, Eur J
Gastroenterol
Hepatol, 2018
University
Hospital
Cirrhosis and
portal
hypertension
Single centre
randomised
clinical trial
11 patients
atorvastatin
+ propranolol vs.
12 placebo
+ propranolol
Atorvastatin One month Change in HVPG Decreased HVPG 4.81 ± 2.82 vs.
2.58 ± 1.88 mmHg
No significant differences in clinical
outcomes after one-year follow-up
aHR, adjusted hazard ratio; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; NA, not available; NASH, non-
alcoholic steatohepatitis; OH, alcohol.
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